# A Clinical Study to Evaluate the Safety and Tolerability of JS012 in Advanced or Metastatic Solid Tumors

> **NCT05388279** · PHASE1 · TERMINATED · sponsor: **Shanghai Junshi Bioscience Co., Ltd.** · enrollment: 3 (actual)

## Conditions studied

- Advanced or Metastatic Solid Tumors

## Interventions

- **DRUG:** JS012
- **COMBINATION_PRODUCT:** JS012 combine with chemotherapy

## Key facts

- **NCT ID:** NCT05388279
- **Lead sponsor:** Shanghai Junshi Bioscience Co., Ltd.
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2022-04-28
- **Primary completion:** 2022-09-19
- **Final completion:** 2022-09-19
- **Target enrollment:** 3 (ACTUAL)
- **Why stopped:** Due to the adjustment and change of the sponsor's R\&D strategy, we now plan to voluntarily terminate this clinical trial.
- **Last updated:** 2023-03-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05388279

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05388279, "A Clinical Study to Evaluate the Safety and Tolerability of JS012 in Advanced or Metastatic Solid Tumors". Retrieved via AI Analytics 2026-06-12 from https://api.ai-analytics.org/clinical/NCT05388279. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*